| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
Purity: ≥98%
Levo-Ornidazole [also known as (S)-Ornidazole; Levornidazole] is the levo-isomer of ornidazole which is a 5-nitroimidazole derivative with antiprotozoal and antibacterial properties against anaerobic bacteria. Levo-Ornidazole is the less active isomer. Ornidazole is a approved drug that cures some protozoan infections. It has been investigated for use in Crohn's disease after bowel resection. Synthesis is a straightforward reaction between 2-methyl-nitroimidazole and epichlorohydrin under acid catalyst conditions. After passive absorption into bacterium cell, the nitro group of ornidazole is reduced to amine group by ferrodoxin type redox system. The formation of redox intermediate intracellular metabolites is believed to be the key component of microorganism killing for Ornidazole. The drug is active against anaerobic bacteria viz. Peptostreptococcus, Clostridium, B. fragilis, Prevotella, Porphyronomas, Fusobacterium and protozoa viz. E. histolytica, T. vaginalis, G. intestinalis etc.
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of use during lactation Ornidazole has not been approved for marketing by the U.S. Food and Drug Administration (FDA), but it is available in other countries. After intravenous administration of three doses totaling 2 grams of ornidazole during the perinatal period, the concentration of ornidazole in breast milk is low. There are currently no reports on plasma drug concentrations in lactating infants. No studies have evaluated adverse reactions of ornidazole to lactating infants, but it is speculated that they are similar to those of the closely related drug metronidazole, such as an increased risk of oral and rectal candidiasis. As with metronidazole, there are concerns about the potential mutagenicity and carcinogenicity of ornidazole in healthy infants through breast milk [1]. Experts disagree on the suitability of long-term use of ornidazole in lactating women, but avoiding breastfeeding for three days after a single dose should reduce the drug concentration in breast milk to a negligible level, as its half-life is similar to that of tinidazole. [2] Other medications are available for treating bacterial vaginosis and can be administered vaginally, thereby reducing the concentration of the drug in breast milk. ◉ Effects on breastfed infants No published information found as of the revision date. ◉ Effects on lactation and breast milk No published information found as of the revision date. |
|---|---|
| References | |
| Additional Infomation |
Reports indicate that (2S)-1-chloro-3-(2-methyl-5-nitroimidazole-1-yl)prop-2-ol exists in Streptomyces, and relevant data are available for reference.
|
| Molecular Formula |
C7H10CLN3O3
|
|---|---|
| Molecular Weight |
219.6256
|
| Exact Mass |
219.041
|
| CAS # |
166734-83-4
|
| Related CAS # |
Ornidazole;16773-42-5
|
| PubChem CID |
6541429
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
443.2±40.0 °C at 760 mmHg
|
| Flash Point |
221.9±27.3 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
0.69
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
211
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=NC=C([N+]([O-])=O)N1C[C@H](O)CCl
|
| InChi Key |
IPWKIXLWTCNBKN-ZCFIWIBFSA-N
|
| InChi Code |
InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3/t6-/m1/s1
|
| Chemical Name |
(2S)-1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
|
| Synonyms |
levornidazole; Ornidazole (Levo-); Ornidazole Levo-; (S)-Ornidazole; Levo-ornidazole; (-)-Tiberal;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (455.31 mM)
H2O : 6.67 mg/mL (30.37 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 3: 10% DMSO+90% (20% SBE-β-CD in Saline): ≥ 2.5 mg/mL (11.38 mM) View More
Solubility in Formulation 4: 25 mg/mL (113.83 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5531 mL | 22.7656 mL | 45.5311 mL | |
| 5 mM | 0.9106 mL | 4.5531 mL | 9.1062 mL | |
| 10 mM | 0.4553 mL | 2.2766 mL | 4.5531 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA